Drugs - 2/164 - Xconomy

Entry	Author	Date	Location
Berwick’s Advice: Cost-Effectiveness Is Here to Stay	John Osborn	04/30/12	National
Biotech IPOs Start to Show Some Modest Signs of Life	Luke Timmerman	04/30/12	National
Taking Open Biology to the Next Level: Notes from the Sage Congress	Stephen Friend	04/27/12	National
SD Life Sciences Roundup: Amylin, Illumina, AstraZeneca Acquires Ardea, & More	Bruce V. Bigelow	04/27/12	San Diego
Genzyme, Epizyme, & Rib-X Among the Week’s Life Sciences Newsmakers	Erin Kutz	04/27/12	Boston
Cardeas Gears Up for Clinic, With Drug Combo for Hospital Infections	Luke Timmerman	04/26/12	Seattle
Cytokinetics Shows Hint of Effect With Drug for Lou Gehrig’s Disease	Luke Timmerman	04/25/12	San Francisco
AstraZeneca Reloads its Pipeline with Ardea Deal, Could be Still Hunting	Bruce V. Bigelow	04/23/12	San Diego
What Are the Hottest Targets in Biotech Today?	Luke Timmerman	04/23/12	National
San Diego’s Q1 Venture Activity Surges on One Mega Deal	Bruce V. Bigelow	04/20/12	San Diego
Dyax, Adimab, Mersana, & More Boston Life Sciences Newsmakers	Erin Kutz	04/20/12	Boston
SD Life Sciences Roundup: Accelrys, Illumina, & RainTree Oncology	Bruce V. Bigelow	04/19/12	San Diego
Cell Therapeutics Shells Out $30M for New Drug	Luke Timmerman	04/19/12	Seattle
Alder Biopharma Snags $38M To Charge Ahead With Antibody Drugs	Luke Timmerman	04/19/12	Seattle
Small is Beautiful in Q1 Venture Deals as VCs Write Lots of Checks	Bruce V. Bigelow	04/18/12	National
Five Questions: Acorda CEO Ron Cohen on the Future of Neurology R&D	Arlene Weintraub	04/17/12	New York
Dendreon CEO John Johnson: ‘This is My Last Stop’	Luke Timmerman	04/17/12	Seattle
Abbott’s Humira, the 3rd-in-Class Drug That Toppled Lipitor as No. 1	Luke Timmerman	04/16/12	National
Tioga Investor Thomas McNerney Keeping Busy After San Diego Move	Bruce V. Bigelow	04/12/12	San Diego
SD Life Sciences Roundup: Optimer, Illumina, & Deals, Deals, Deals	Bruce V. Bigelow	04/12/12	San Diego
BioPharma Needs A Safe, Reliable Way To Repair Broken Genes	Stewart Lyman	04/11/12	Seattle
UCSD Spinoff NexDx Aims to Diagnose Rheumatoid Arthritis	Bruce V. Bigelow	04/11/12	San Diego
AisleBuyer, Crashlytics, Cymfony, & More Boston Dealmakers	Erin Kutz	04/11/12	Boston
Oncothyreon Marches On With ‘Son of Stimuvax’ Cancer Vaccine	Luke Timmerman	04/10/12	Seattle
Optimer Discloses Shakeup Prompted by Chairman’s Deal in Taiwan	Bruce V. Bigelow	04/09/12	National
AVI Biopharma Mulls Deal After Mixed Data With Muscular Dystrophy Drug	Luke Timmerman	04/06/12	Seattle
Adimab, ImmunoGen, OvaScience, & More Boston Life Sciences News	Erin Kutz	04/06/12	Boston
SD Life Sciences Roundup: Illumina, Sophiris Bio, & New Funding Deals	Bruce V. Bigelow	04/05/12	San Diego
Reinventing Biotech’s Business Model: The Photo Gallery	Luke Timmerman	04/04/12	Seattle
AVI Biopharma Passes Small Study in Muscular Dystrophy	Luke Timmerman	04/02/12	Seattle
Page 2 of 55	« previous page · next page »

Entry

Author

Date

Location

Berwick’s Advice: Cost-Effectiveness Is Here to Stay

John Osborn

04/30/12

National

Biotech IPOs Start to Show Some Modest Signs of Life

Luke Timmerman

04/30/12

National